Market Introduction
Biomarkers are disease-specific indicators. Advancements in biotechnology have enabled the measurement of specific biomarkers responsible for various neurological diseases that was not possible earlier. The rising adoption of these biomarkers have helped in the early detection, less invasive diagnosis and faster drug development for neurological disorders.
Market Overview and Dynamics
The North America neurological biomarkers market is expected to reach US$ 2,618.68 Mn in 2027 from US$ 7,056.76 Mn in 2019. The market is estimated to grow with a CAGR of 13.4% from 2020-2027. Factors such as growing prevalence of neurological disorders and increasing focus toward research in neurological biomarker are expected to fuel the growth of the market. However, the limitation of neurological biomarkers is a major factor hindering the market growth.
Key Market Segments
Based on product, in 2019, the genomic biomarkers segment held the largest share of the market and is expected to grow at the fastest CAGR during the forecast period. This segment is likely to witness a lucrative growth owing to increasing awareness among consumers regarding benefits of genetic medicines as well as technological advancements in the field of neurological biomarkers. In addition, the trend shift towards adoption of gene counseling and genetic analysis for diagnostic purposes is also likely to augment the growth of the segment. The genetic biomarkers are significant modalities that directs towards a more personalized approach of predispositions and medical analysis.
Major Sources and Companies Listed
Some of the major primary and secondary sources forNeurological Biomarkersmarket included in the report are, World Health Organization (WHO), Food and Drug Administration (FDA), National Institute of Neurological Disorders and Stroke (NINDS), Centers for Disease Control and Prevention (CDC), and others.
Reasons to buy the report
NORTH AMERICANEUROLOGICAL BIOMARKERSMARKET SEGMENTATION
By Product
ByApplication
By End User
By Geography
• North America
Company Profiles
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 7,056.76 Million |
| Market Size by 2027 | US$ 2,618.68 Million |
| CAGR (2020 - 2027) | 13.4% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Product
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
The North America Neurological Biomarkers Market is valued at US$ 7,056.76 Million in 2019, it is projected to reach US$ 2,618.68 Million by 2027.
As per our report North America Neurological Biomarkers Market, the market size is valued at US$ 7,056.76 Million in 2019, projecting it to reach US$ 2,618.68 Million by 2027. This translates to a CAGR of approximately 13.4% during the forecast period.
The North America Neurological Biomarkers Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Neurological Biomarkers Market report:
The North America Neurological Biomarkers Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Neurological Biomarkers Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Neurological Biomarkers Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Neurological Biomarkers Market
